Afibrinogenemia is a rare congenital coagulopathy that leads to life-threatening bleeding. In afibrinogenemia, plasma fibrinogen levels are less than 0.1 g/L. The clinical manifestations of the disease can be both bleeding and thromboses of different localizations, which is determined by the multifunctional role of fibrinogen in hemostasis. The described cases demonstrate different clinical phenotypes of the disease. In both cases the diagnosis was confirmed by genetic examinations that revealed homozygous mutations in the fibrinogen A genes. The nature of the mutations assumes consanguineous marriages, as confirmed by the results of a genealogical analysis. Fibrinogen preparations are promising in treating afibrinogenemia in Russia.

Download full-text PDF

Source
http://dx.doi.org/10.17116/terarkh20168812120-125DOI Listing

Publication Analysis

Top Keywords

[hereditary afibrinogenemia
4
afibrinogenemia literature
4
literature review
4
review clinical
4
clinical observations]
4
observations] afibrinogenemia
4
afibrinogenemia rare
4
rare congenital
4
congenital coagulopathy
4
coagulopathy leads
4

Similar Publications

Objective To investigate the classification, clinical manifestations, laboratory findings, and genetic mutations associated with hereditary fibrinogen disorders in Chinese population. Methods Between February 2015 and February 2022, 65 patients with congenital fibrinogen disorders (CFD) were identified at Wuhan Union Hospital. Comprehensive data were available for 51 patients, allowing for a retrospective analysis.

View Article and Find Full Text PDF
Article Synopsis
  • * This study compares the bleeding profiles and quality of life (QOL) of women and girls with hemophilia to those with VWD and rare bleeding disorders, using the ISTH Bleeding Assessment Tool and the EuroQOL questionnaire.
  • * Initial findings showed that 80 participants were enrolled, with a median age of 35 for hemophilia carriers and 15.5 for those with diagnosed bleeding disorders, revealing a significant family history of bleeding disorders in both groups.
View Article and Find Full Text PDF
Article Synopsis
  • Rare bleeding disorders (RBDs) encompass inherited coagulation and vascular bleeding disorders, including fibrinogen and platelet function disorders, with challenges in management despite advancements in understanding their biology and diagnosis.
  • Current treatments primarily focus on replacing a few coagulation factors and developing new therapeutic agents, but optimal strategies for specific conditions like severe IPFD and afibrinogenemia are still under debate.
  • There is ongoing research into effective therapies for hereditary hemorrhagic telangiectasia (HHT) and a need to evaluate dosing, safety, and the impact of treatments on related conditions.
View Article and Find Full Text PDF

Obstetrical complications in hereditary fibrinogen disorders: the Fibrinogest study.

J Thromb Haemost

August 2023

Division of Angiology and Hemostasis, University Hospitals of Geneva, Faculty of Medicine, Geneva, Switzerland. Electronic address:

Background: Women with hereditary fibrinogen disorders (HFDs) seem to be at an increased risk of adverse obstetrical outcomes, but epidemiologic data are limited.

Objectives: We aimed to determine the prevalence of pregnancy complications; the modalities and management of delivery; and the postpartum events in women with hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia.

Methods: We conducted a retrospective and prospective multicentric international study.

View Article and Find Full Text PDF

[Genetic analysis of two Chinese pedigrees affected with Hereditary hypofibrinemia due to missense variants].

Zhonghua Yi Xue Yi Chuan Xue Za Zhi

March 2023

Center of Laboratory Medicine, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, China.

Objective: To retrospectively analyze the clinical phenotypes and genetic variants in two Chinese pedigrees affected with Hereditary hypofibrinemia (IFD) and explore their molecular pathogenesis.

Methods: Two probands and their pedigree members were admitted to the First Affiliated Hospital of Wenzhou Medical University on March 30, 2021 and May 27, 2021, respectively. Clinical phenotypes of the probands were collected, and blood clotting indexes of the probands and their pedigree members were determined.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!